Oncology

Servier
Favicon Fierce Pharma

Servier rounds out rare cancer offerings with $2.5B Day One buy

Servier has unveiled a deal to acquire commercial-stage Day One Biopharmaceuticals and its med Ojemda for $21.50 per share in cash.
Fraiser Kansteiner Mar 6, 2026 10:14am
Takeda

Takeda inks $1.7B AI discovery deal with Iambic Therapeutics

Feb 9, 2026 8:00am
A ballpoint pen rests on top of a stack of documents ready for signing

Lilly, Innovent pen $8.8B collab 'beyond traditional licensing'

Feb 9, 2026 6:45am
IPO initial public offering Wall Street

Eikon upsized $381M listing marks largest biotech IPO since 2024

Feb 5, 2026 4:23am
Red and white pawns with golden arrows Employee swap or turnover concept

Moderna's latest CMO steps down after barely a year

Jan 30, 2026 10:58am
money funding financing bank

Eikon sets $274M goal for upcoming stock market debut

Jan 28, 2026 2:00pm
More News

Fortitude has faith glue degraders can beat ADC resistance

Jan 26, 2026 10:47am

Cancer imaging company buys Lisata for ph. 2-stage tumor drug

Jan 21, 2026 9:20am

Worldwide Clinical Trials adds Catalyst to global CRO mixture

Jan 20, 2026 2:54pm

JPM26: Gilead eyes new deals from a 'position of strength'

Jan 14, 2026 3:30am